Overview

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL

Status:
Not yet recruiting

Trial end date:
2031-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in relapsed or refractory DLBCL.

Phase:

Phase 2

Details

Lead Sponsor:

Xencor, Inc.

Treatments:

Lenalidomide